Lakefront Biotherapeutics (LKFT) Current Deferred Revenue (2013 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Current Deferred Revenue of $37463.9 for Q1 2026, down 99.98% year-over-year from $242.6 million in Q1 2025, and up 0.58% quarter-over-quarter from $37249.4 in Q4 2025.
Powered by 
Analysis
Lakefront Biotherapeutics (LKFT) Current Deferred Revenue (2013 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Current Deferred Revenue for 13 consecutive years, with $37463.9 the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Deferred Revenue fell 99.98% year-over-year to $37463.9; the TTM figure through Mar 2026 stood at $37463.9 (down 99.98% YoY), while the FY2025 annual figure was $37249.4, down 99.99% from the prior year.
- Current Deferred Revenue rose to $37463.9 in Q1 2026 per LKFT's latest filing, from $37249.4 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $469.3 million in Q1 2022 and bottomed at $37249.4 in Q4 2025.
- Historically, Current Deferred Revenue has averaged $258.9 million across 5 years, with a median of $260.6 million in 2025.
- On a YoY basis, Current Deferred Revenue climbed as much as 6.08% in 2025 and fell as far as 99.99% in 2025.
- Lakefront Biotherapeutics' Current Deferred Revenue stood at $373.0 million in 2022, then declined by 26.08% to $275.7 million in 2023, then decreased by 9.9% to $248.4 million in 2024, then slumped by 99.99% to $37249.4 in 2025, then advanced by 0.58% to $37463.9 in 2026.
- Business Quant data shows LKFT's Current Deferred Revenue at $37463.9 in Q1 2026, $37249.4 in Q4 2025, and $269.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | Lakefront Biotherapeutics | 1.88 Bn | 1.88 Bn | 3.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 37,463.86 |
| Dec 31, 2025 | 37,249.39 |
| Sep 30, 2025 | 269.02 Mn |
| Jun 30, 2025 | 260.62 Mn |
| Mar 31, 2025 | 242.60 Mn |
| Dec 31, 2024 | 248.42 Mn |
| Sep 30, 2024 | 253.62 Mn |
| Mar 31, 2024 | 252.54 Mn |
| Dec 31, 2023 | 275.73 Mn |
| Sep 30, 2023 | 343.41 Mn |
| Mar 31, 2023 | 377.08 Mn |
| Dec 31, 2022 | 373.03 Bn |
| Mar 31, 2022 | 469.28 Mn |
| Dec 31, 2021 | 480.31 Bn |
| Jun 30, 2021 | 503.47 Mn |
| Dec 31, 2020 | 528.37 Bn |
| Jun 30, 2020 | 444.61 Mn |
| Mar 31, 2020 | 462.63 Mn |
| Dec 31, 2019 | 458.58 Mn |
| Sep 30, 2019 | 521.61 Mn |